Novel melanoma therapy

被引：9
作者：
Hsueh E.C. [1 ]
Gorantla K.C. [1 ]
机构：
[1] Saint Louis University, Division of General Surgery, Department of Surgery, 3635 Vista at Grand Blvd, St. Louis, 63110, MO
来源：
Experimental Hematology & Oncology | / 5卷 / 1期
关键词：
Checkpoint inhibitors; Metastatic melanoma; Targeted therapy;
D O I：
10.1186/s40164-016-0054-1
中图分类号：
学科分类号：
摘要：
With the rapid succession of new effective agents for melanoma in the recent years, the paradigm for treatment of metastatic melanoma is changing. The success of combining multiple effective agents compared with outcomes of monotherapy also brings increasing complexity in the treatment algorithm for various subsets of metastatic melanoma patients. We reviewed the recent reports on novel melanoma therapy to shed light on rational decision-making in treating these patients. © 2016 The Author(s).
引用
收藏
相关论文
共 84 条
[1]  
Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., Et al., Improved survival with ipilimumab in patients with metastatic melanoma, N Engl J Med, 363, 8, pp. 711-723, (2010)
[2]  
Chapman P., Hauschild A., Robert C., Haanen J., Ascierto P., Larkin J., Et al., Improved survival with vemurafenib in melanoma with BRAF V600E mutation, N Engl J Med, 364, 26, pp. 2507-2516, (2011)
[3]  
Ascierto P., Minor D., Ribas A., Lebbe C., O'Hagan A., Arya N., Et al., Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma, J Clin Oncol, 31, 26, pp. 3205-3211, (2013)
[4]  
Flaherty K.T., Infante J.R., Daud A., Gonzalez R., Kefford R.F., Sosman J., Et al., Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations, N Engl J Med, 367, 18, pp. 1694-1703, (2012)
[5]  
Robert C., Ribas A., Wolchok J.D., Hodi F.S., Hamid O., Kefford R., Et al., Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial, Lancet, 384, 9948, pp. 1109-1117, (2014)
[6]  
Topalian S.L., Sznol M., McDermott D.F., Kluger H.M., Carvajal R.D., Sharfman W.H., Et al., Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab, J Clin Oncol, 32, 10, pp. 1020-1030, (2014)
[7]  
Davies H., Bignell G., Cox C., Stephens P., Edkins S., Clegg S., Et al., Mutations of the BRAF gene in human cancer, Nature, 417, 6892, pp. 949-954, (2002)
[8]  
Hauschild A., Grob J.J., Demidov L.V., Jouary T., Gutzmer R., Millward M., Et al., Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial, Lancet, 380, 9839, pp. 358-365, (2012)
[9]  
Sosman J.A., Kim K.B., Schuchter L., Gonzalez R., Pavlick A.C., Weber J.S., Et al., Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib, N Eng J Med., 366, 8, pp. 707-714, (2012)
[10]  
Shi H., Hugo W., Kong X., Hong A., Koya R.C., Moriceau G., Et al., Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy, Cancer Discov., 4, 1, pp. 80-93, (2014)
123456789